VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
RVMD
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
RVMDRevolution Medicines, Inc.
$162.69$34.6B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. RVMD
  4. Financial Ratios

Revolution Medicines, Inc. (RVMD) Financial Ratios

Latest Ratios: P/E Ratio -18.7x · EV/EBITDA N/A · ROE -58.1%. (2017–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

RVMD Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Market Cap$34.6B$15.1B$7.3B$3.2B$1.9B$1.8B$2.6B———
Enterprise Value$34.4B$14.9B$6.9B$2.6B$1.8B$1.8B$2.6B———
P/E Ratio →-18.69—————————
P/S Ratio175.07——280.2454.2862.3561.34———
P/B Ratio18.969.283.241.782.803.045.55———
P/FCF——————————
P/OCF——————————

P/E links to full P/E history page with 30-year chart

RVMD EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
EV / Revenue———227.7151.5460.9359.68———
EV / EBITDA——————————
EV / EBIT——————————
EV / FCF——————————

RVMD Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Gross Margin———100.0%100.0%100.0%100.0%100.0%100.0%—
Operating Margin———-4207.1%-730.0%-639.7%-257.5%-108.2%-200.0%—
Net Profit Margin———-3768.3%-703.0%-636.6%-251.6%-95.2%-207.2%—

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
ROE-58.1%-58.1%-29.3%-34.8%-38.6%-34.7%-34.5%-38.3%-82.6%-687.0%
ROA-46.1%-46.1%-26.0%-30.4%-32.1%-28.7%-27.5%-24.4%-45.0%-206.5%
ROIC-54.3%-54.3%-33.6%-40.5%-33.7%-29.3%-30.8%-49.8%-266.8%—
ROCE-53.0%-53.0%-32.0%-36.5%-36.2%-31.4%-31.7%-34.1%-54.7%-416.2%

RVMD Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Debt / Equity0.100.100.060.050.090.110.07—0.00—
Debt / EBITDA——————————
Net Debt / Equity—-0.14-0.18-0.33-0.14-0.07-0.15-0.11-0.72-2.00
Net Debt / EBITDA——————————
Debt / FCF——————————
Interest Coverage-45.69-45.69—-1450.79—-15589.92-1527.59-489.92-359.25-301.20

Net cash position: cash ($384M) exceeds total debt ($159M)

RVMD Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Current Ratio7.147.1414.2013.0610.659.779.633.112.801.24
Quick Ratio7.147.1414.2013.0610.659.779.633.112.581.24
Cash Ratio6.976.9713.9712.8810.409.569.342.852.281.19
Asset Turnover———0.010.040.040.080.230.12—
Inventory Turnover——————————
Days Sales Outstanding———39.5348.2173.6354.2963.73132.19—

RVMD Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Dividend Yield——————————
Payout Ratio——————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Earnings Yield——————————
FCF Yield——————————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%———
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%———
Shares Outstanding—$190M$168M$113M$81M$73M$67M$36M$36M$36M

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Sustained operating cash burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Premium Pricing Without Earnings Support

According to reported quarterly figures, RVMD trades at a P/S of 206.92 and P/B of 22.41 with a negative trailing P/E of -22.10, meaning the market is pricing a pipeline outcome rather than any current earnings or revenue base.

Traditional earnings multiples are not meaningful here because net income is negative in every period shown, so the valuation rests almost entirely on sales and book value ratios. The P/S multiple of over 200 reflects a single recent revenue print against a large equity base, which suggests investors are capitalizing future commercialization rather than observed cash generation. Investors should monitor whether the implied growth expectations remain supportable if revenue fails to recur at the 2026Q3 level.

Debt Layering Against Negative Coverage

Based on reported figures, D/E rose from 0.05 in 2024Q3 to 0.27 in 2026Q3 while interest coverage stands at -11.12, indicating borrowing has increased even though operating earnings do not cover interest expense.

Leverage remains modest in absolute terms with total debt near $639M against equity of $2.4B, yet the negative interest coverage shows debt service is not supported by operating income. The step-up in borrowing during 2026 appears to be a deliberate financing choice rather than a response to operating cash generation. Warrants further investigation into the debt maturity profile and covenant terms, which are not provided in the supplied data.

Strong Current Ratio Masks Burn Exposure

As reported in the balance sheet, the current ratio of 8.36 in 2026Q3 looks comfortable, but cash fell from $815.4M to $615.9M in one quarter, pointing to a short runway if the free cash flow deficit persists near $419M per quarter.

A current ratio above 8 and quick ratio nearly identical to it indicate that liquid assets dominate current liabilities and inventory is not a meaningful factor. However, the ratio is a snapshot that does not capture the pace of cash consumption. Based on reported figures, the quarterly burn rate suggests the headline liquidity position may overstate how long current resources can fund operations without new capital.

Working Capital Timing Distorts Burn

Based on reported quarterly data, DPO of 26,598 days and CCC of -23,390 days are not economically interpretable for this business, reflecting near-zero cost of goods rather than genuine supplier leverage.

The efficiency ratios are dominated by the absence of a meaningful cost of sales base, so DIO and DPO values are extreme and should not be read as operating advantages. Working capital swings of over $140M between quarters indicate that accrual and payable timing drives reported burn more than operating trends. Analysts should focus on the cash balance trajectory rather than these conversion metrics.

Headline Liquidity Overstates Durable Funding

Based on reported figures, the strong current ratio may lead readers to underestimate how quickly a free cash flow deficit above $400M per quarter could erode the cash balance absent new financing.

The most misleading signal in this dataset is the 8.36 current ratio, which describes the composition of the balance sheet rather than its duration. Stock-based compensation of $62.6M to $87.3M per quarter reduces the reported loss but does not reduce the cash that must be funded. Investors should treat future financing access as a central assumption that warrants monitoring rather than a given.

Download Financial Ratios Data

Includes 30+ ratios · 9 years · Updated daily

Consensus & Technical Research Suite
Open RVMD Terminal

RVMD Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

RVMD — Frequently Asked Questions

Quick answers to the most common questions about buying RVMD stock.

What is Revolution Medicines, Inc.'s P/E ratio?

Revolution Medicines, Inc.'s current P/E ratio is -18.7x. This places it at the 50th percentile of its historical range.

What is Revolution Medicines, Inc.'s ROE?

Revolution Medicines, Inc.'s return on equity (ROE) is -58.1%. The historical average is -43.9%.

Is RVMD stock overvalued?

Based on historical data, Revolution Medicines, Inc. is trading at a P/E of -18.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.